Powerful New Predictor of sPTB: Proteomics5
An analysis of 5,501 women in a landmark, prospective study—Proteomic Assessment of Preterm Risk or ‘PAPR’—published in American Journal of Obstetrics and Gynecology, showed that several distinct proteins measured in maternal serum are effective predictors of sPTB early in pregnancy before symptoms occur. The PAPR Study was conducted from 2011-2014 at eleven highly-respected clinical sites across the U.S.
Sera Prognostics developed a biomarker signature for sPTB using proteomic technology. The signature was validated to predict spontaneous preterm birth (sPTB) risk by measuring proteins that are over- or under-expressed and are predictive of premature birth (or delivery).
The PreTRM test is highly predictive of preterm delivery in asymptomatic, singleton pregnancies between 19-20 weeks gestational age. The sPTB prediction resulted in an Area Under the Curve (AUC) ranging between 0.75 and 0.93.5
were discovered in this landmark study — a large contemporary, multisite, all-comer study. Eleven highly-respected clinical sites across the U.S. participated.
were prospectively collected from 5,501 women between 17-28 weeks gestation. This is the largest study of its kind and is representative of the intended use U.S. pregnant population.
including proteomics, bioinformatics, and multidimensional data analysis was applied to PAPR samples to validate a proprietary biomarker signature designed to accurately predict a woman’s individual risk of delivering preterm. Validation and verification of target proteins was completed in 2015.
Non-Predictive vs Predictive Protein Expression in Pregnancy5
This example represents a pregnancy-related protein that is unaffected by preterm pathology.
Under-Expressed Protein (SHBG):
This example represents a biologically-important protein that is under-expressed in patients who went on to have sPTB.
Over-Expressed Protein (IBP4):
This example represents a biologically-important protein that is over-expressed in patients who went on to have sPTB.